Haemonetics Corporation $HAE Stock: Boston Trust Walden Corp Cuts Position

Boston Trust Walden Corp lowered its holdings in Haemonetics Corporation (NYSE:HAE) by 34.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 385,355 shares of the medical instruments supplier’s stock after selling 199,793 shares during the quarter. Boston Trust Walden Corp’s holdings in Haemonetics were worth $40,578,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HAE. Fortitude Family Office LLC boosted its position in Haemonetics by 104.5% in the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 139 shares during the last quarter. Kelleher Financial Advisors bought a new position in shares of Haemonetics in the 2nd quarter worth about $38,000. Root Financial Partners LLC bought a new stake in shares of Haemonetics in the 3rd quarter worth approximately $40,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Haemonetics during the second quarter worth about $44,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Haemonetics in the 2nd quarter valued at approximately $54,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HAE. JPMorgan Chase & Co. upped their price objective on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Mizuho upped their target price on Haemonetics from $95.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. Raymond James Financial raised their target price on Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, September 3rd. BTIG Research lifted their price target on shares of Haemonetics from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 8th. Finally, Citigroup raised their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Haemonetics Stock Up 5.9%

Shares of HAE opened at $127.40 on Thursday. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 24.01, a P/E/G ratio of 2.40 and a beta of 0.63. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. Haemonetics Corporation has a 12 month low of $49.96 and a 12 month high of $128.83. The company has a 50-day moving average price of $110.86 and a two-hundred day moving average price of $79.55.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The company had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. During the same period last year, the business earned $1.10 earnings per share. The business’s revenue was up 5.5% on a year-over-year basis. Equities analysts predict that Haemonetics Corporation will post 5.29 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.